Denosumab Production Cost Reports

The report provides a detailed analysis essential for establishing a denosumab production plant. It encompasses all critical aspects necessary for denosumab production, including the cost of denosumab production, denosumab plant cost, denosumab production costs, and the overall denosumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a denosumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Denosumab (sold under brand names Prolia and Xgeva) is a human monoclonal antibody utilised in the pharmaceutical sector. It is a prescription medication that strengthens bones and reduces fracture risk by inhibiting a protein (RANKL) that triggers bone breakdown. It prevents bone resorption to treat postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, bone metastases-related skeletal events, and giant cell tumours of bone.

Denosumab’s market growth is driven by the rising global prevalence of osteoporosis, mainly among ageing populations, along with increasing incidences of bone metastases from cancers like breast, prostate, and multiple myeloma, which heighten demand for its bone-protective effects. The regulatory approvals for expanded indications, such as glucocorticoid-induced osteoporosis and giant cell tumours of bone, further boost adoption. Additionally, advancements in biosimilar development and strategic partnerships among major players enhance accessibility and affordability.

The heightened awareness of bone health, innovations in cancer therapies, and strong growth in emerging markets like the Asia-Pacific due to demographic shifts and healthcare investments propel market expansion. Furthermore, quality specifications, including purity levels, grade matching, and control of post-translational modifications, impact industrial denosumab procurement, along with supplier reliability assessed via audit history and pilot batch availability.

Raw Material for Denosumab Production

According to the denosumab production plant project report, the various raw materials for denosumab production include Chinese hamster ovary cells.

Production Process of Denosumab

The extensive denosumab production cost report consists of the following major industrial production process:

1. Production via a batch-wise fed-batch cell culture process: The production process of denosumab initiates by using recombinant DNA technology in Chinese hamster ovary (CHO) cells through a batch-wise fed-batch cell culture process in production bioreactors. The process is followed by harvest via centrifugation and membrane filtration to obtain clarified supernatant. The downstream purification process begins with protein A affinity chromatography for initial capture, followed by polishing via cation exchange and hydrophobic interaction chromatography, viral inactivation through low pH hold, and viral removal by nanofiltration. The process concludes with ultrafiltration/diafiltration to produce a sterile, pH-adjusted (around 5.2) bulk drug substance.

Properties of Denosumab

Denosumab is a fully human IgG2 monoclonal antibody with a molecular weight of 144,700 Da, consisting of two heavy chains (448 amino acids each) and two light chains (215 amino acids each), along with four intramolecular disulfide bonds, and a protein chemical formula of C6404H9912N1724O2004S50. As a sterile aqueous solution for injection, it appears clear, colourless to pale yellow or slightly yellow, and odourless, with a pH of around 5.2, high water solubility, and density like water. It is chemically stable under normal conditions and has high binding affinity (Kd = 3 × 10^-12 mol/L) to RANKL, inhibiting osteoclast activity without reactivity hazards unless exposed to strong oxidising agents, heat, flames, or sparks.